Table 1 Comparison of patient characteristics between ConT and TAE groups

Patients (n)

48

32

16

Age

69.3 ± 8.1

70.2 ± 8.7

67.5 ± 6.6

NS

Sex (n, %)

   Male

36 (75%)

22 (69%)

14 (87%)

NS

   Female

12 (25%)

10 (31%)

2 (13%)

Etiology of LC (n, %)

   HCV

32 (67%)

21 (65%)

11 (69%)

   HBV

4 (8%)

3 (9%)

1 (6%)

NS

   Alcohol

5 (10%)

4 (13%)

1 (6%)

   NonB-nonC

7 (15%)

4 (13%)

3 (19%)

Past history of HCC treatment (n, %)

   presence

36 (75%)

24 (75%)

12 (75%)

NS

   absence

12 (25%)

8 (25%)

4 (25%)

Admission duration for the treatment of HCC

3.0 ± 2.8

3.2 ± 2.9

2.6 ± 2.7

NS

Months from first treatment of HCC

31.0 ± 32.7

35.2 ± 36.4

22.8 ± 22.3

NS

Shock (n, %)

   presence

22 (48%)

16 (50%)

6 (38%)

NS

   absence

26 (52%)

16 (50%)

10 (62%)

Albumin (g/dL)

3.2 ± 0.4

3.1 ± 0.5

3.3 ± 0.3

NS

Total bilirubin (mg/dL)

1.8 ± 0.9

1.9 ± 0.9

1.5 ± 0.7

NS

PT (INR)

1.25 ± 0.13

1.24 ± 0.12

1.29 ± 0.16

NS

ICG at 15 min

33.1 ± 13.2

32.9 ± 12.9

33.5 ± 14.2

NS

AFP (ng/mL)

59163

84009

9472

NS

PIVKA-II (mAU/mL)

39589

55199

8370

NS

Ascites (n, %)

   presence

32 (67%)

23 (72%)

9 (56%)

NS

   absence

16 (33%)

9 (28%)

7 (44%)

Hepatic encephalopathy (n, %)

   presence

25 (52%)

17 (53%)

8 (50%)

NS

   absence

23 (48%)

15 (47%)

8 (50%)

AST (IU/L)

91 ± 73

94 ± 79

76 ± 51

NS

ALT (IU/L)

53 ± 35

52 ± 35

53 ± 35

NS

Hemoglobin (g/dL)

11.5 ± 1.9

11.1 ± 1.9

12.2 ± 1.8

NS

Platelet count (× 10⁴)

14.9 ± 7.8

14.1 ± 6.0

16.6 ± 10.5

NS

Creatinine (mg/dL)

1.03 ± 0.66

1.08 ± 0.75

0.92 ± 0.42

NS

Child-Pugh classification (n, %)

   A

12 (24%)

7 (22%)

5 (31%)

   B

18 (38%)

11 (34%)

7 (44%)

NS

   C

18 (38%)

14 (44%)

4 (25%)

Child-Pugh score

8.0 ± 2.1

8.2 ± 2.1

7.8 ± 1.9

NS

Number of tumors (n, %)

   single

6 (13%)

2 (6%)

4 (25%)

NS

   multiple

42 (87%)

30 (94%)

12 (75%)

Maximum tumor size (cm)

7.0 ± 2.0

7.1 ± 3.9

6.9 ± 2.8

NS

Maximum tumor size (n, %)

   ≤ 7 cm

23 (48%)

15 (47%)

8 (50%)

NS

   > 7 cm

25 (52%)

17 (53%)

8 (50%)

Portal vein tumor thrombosis

   presence

24 (50%)

16 (50%)

8 (50%)

NS

   absence

24 (50%)

16 (50%)

8 (50%)

Clinical stage

   II

1 (4%)

0 (0%)

1 (6%)

   III

22 (44%)

12 (38%)

10 (63%)

NS

   IVA

15 (31%)

11 (34%)

4 (25%)

   IVB

10 (21%)

9 (28%)

1 (6%)